Kazia Therapeutics Limite...

0.89
-0.05 (-5.29%)
At close: Feb 14, 2025, 3:59 PM
0.92
2.81%
After-hours Feb 14, 2025, 04:39 PM EST
undefined%
Bid n/a
Market Cap 2.96M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -6.4
PE Ratio (ttm) -0.14
Forward PE n/a
Analyst Buy
Ask 0.92
Volume 180,521
Avg. Volume (20D) 1,900,273
Open 0.95
Previous Close 0.94
Day's Range 0.89 - 0.99
52-Week Range 0.89 - 15.80
Beta undefined

About KZIA

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Thera...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 6, 1999
Employees 9
Stock Exchange NASDAQ
Ticker Symbol KZIA

Analyst Forecast

According to 2 analyst ratings, the average rating for KZIA stock is "Buy." The 12-month stock price forecast is $11.5, which is an increase of 1192.13% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
2 weeks ago
+37.68%
Kazia Therapeutics shares are trading higher follo... Unlock content with Pro Subscription
1 month ago
-42.9%
Kazia Therapeutics shares are trading lower after the FDA announced the secondary endpoint data on OS from the GBM-AGILE study would not be appropriate for accelerated approval.